Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 15;214(10):1492-1497.
doi: 10.1093/infdis/jiw412. Epub 2016 Sep 7.

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

Christoph Höner Zu Siederdissen  1 , Franziska Rinker  1   2 , Benjamin Maasoumy  1 , Steffen B Wiegand  1 , Natalie Filmann  3 , Christine S Falk  4 , Katja Deterding  1 , Kerstin Port  1 , Carola Mix  1 , Michael P Manns  1   4   2 , Eva Herrmann  3 , Heiner Wedemeyer  1   4   2 , Anke R M Kraft  1   2 , Markus Cornberg  1   2
Affiliations

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

Christoph Höner Zu Siederdissen et al. J Infect Dis. .

Abstract

This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was associated with induction of plasma tumor necrosis factor, interleukin (IL) 10 , IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-term follow-up. The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of therapy were positively correlated with the level of HBsAg decline at week 48. Thus, stopping or interrupting NA treatment should be further investigated as a strategy to accelerate HBsAg loss.

Keywords: CXCL10; HBsAg; IP-10; cytokines; hepatitis B virus infection; nucleos(t)ide analogues; stopping treatment.

PubMed Disclaimer

Publication types

MeSH terms